Full story (not investment advice): https://www.merlintrader.com/vaxcyte-stock-hub/
Full story (not investment advice): https://www.merlintrader.com/vaxcyte-stock-hub/
Off-exchange trading by session (share of volume): Nov 13 209,217 (33.6%).
The dark pool ratio Nov 13 was 0.2x normal and the 5-day trend is fading.
Full story at the link.
#optionsflow #stocks #optionstrading #stockmarket
Off-exchange trading by session (share of volume): Nov 13 209,217 (33.6%).
The dark pool ratio Nov 13 was 0.2x normal and the 5-day trend is fading.
Full story at the link.
#optionsflow #stocks #optionstrading #stockmarket
$30K traded in #$PCVX options, split $29K calls / $1,912 puts (94% calls).
Nov 11: dark pool volume 0.6x normal, trending fading across 5 sessions.
Full story at the link.
#darkpool #stocks #stockmarket
$30K traded in #$PCVX options, split $29K calls / $1,912 puts (94% calls).
Nov 11: dark pool volume 0.6x normal, trending fading across 5 sessions.
Full story at the link.
#darkpool #stocks #stockmarket
Hub: https://www.merlintrader.com/vaxcyte-stock-hub/
Newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13
Hub: https://www.merlintrader.com/vaxcyte-stock-hub/
Newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13
https://www.merlintrader.com/vaxcyte-stock-hub/
https://www.merlintrader.com/vaxcyte-stock-hub/
• Holder: T. Rowe Price Investment Management
• Stake: 9.6% → 11.6% (about $1.1B)
• Shares: 14,312,368 → 18,136,166
• Filed: Nov 6 · Schedule 13G/A
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#Investing #Stocks
• Holder: T. Rowe Price Investment Management
• Stake: 9.6% → 11.6% (about $1.1B)
• Shares: 14,312,368 → 18,136,166
• Filed: Nov 6 · Schedule 13G/A
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#Investing #Stocks
• Holder: T. Rowe Price Investment Management
• Stake: now 9.6% (about $886M)
• Filed: Nov 6 · Schedule 13G/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#Investing #Stocks #13G #ElixStocks
• Holder: T. Rowe Price Investment Management
• Stake: now 9.6% (about $886M)
• Filed: Nov 6 · Schedule 13G/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#Investing #Stocks #13G #ElixStocks
#$PCVX FAQ + PDF report: www.merlintrader.com/vaxcyte-stoc...
#$PCVX FAQ + PDF report: www.merlintrader.com/vaxcyte-stoc...
Cowan Elvia (SVP, Finance & CAO) sold 3,000 shares at an average price of $60.9178 per common share. (Date: 2026-11-02)
Cowan Elvia (SVP, Finance & CAO) sold 3,000 shares at an average price of $60.9178 per common share. (Date: 2026-11-02)
https://fundspec.ai/s/PCVX/earnings
Stress test revenue, margin and WACC to see the real upside and downside.
https://fundspec.ai/s/PCVX/earnings
Stress test revenue, margin and WACC to see the real upside and downside.
Wassil Jim (EVP, Chief Scientific Ofc, COO) sold 2,250 shares at an average price of $60.8996 per common share. (Date: 2026-11-02)
Wassil Jim (EVP, Chief Scientific Ofc, COO) sold 2,250 shares at an average price of $60.8996 per common share. (Date: 2026-11-02)
https://www.stocktitan.net/news/PCVX/vaxcyte-reports-third-quarter-2026-financial-results-and-provides-cbqda9nvur0i.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/PCVX/vaxcyte-reports-third-quarter-2026-financial-results-and-provides-cbqda9nvur0i.html?utm_source=stocktitan-bluesky&utm_medium=social
On November 4, 2026, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.
On November 4, 2026, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.
Cowan Elvia, a Officer, filed a notice of intent to sell 3,000 shares of common stock, valued at approximately $185,640.00, on 11/02/2026.
Cowan Elvia, a Officer, filed a notice of intent to sell 3,000 shares of common stock, valued at approximately $185,640.00, on 11/02/2026.
PCVX Stock Hub: Vaxcyte News, Operations and Capital
www.merlintrader.com/vaxcyte-stoc...
PCVX Stock Hub: Vaxcyte News, Operations and Capital
www.merlintrader.com/vaxcyte-stoc...
Adult versus pediatric vaccines, trial endpoints and what immunogenicity can establish.
https://www.merlintrader.com/pcvx-mrk-pfe-sny-pneumococcal-vaccine-catalyst-comparison/
Adult versus pediatric vaccines, trial endpoints and what immunogenicity can establish.
https://www.merlintrader.com/pcvx-mrk-pfe-sny-pneumococcal-vaccine-catalyst-comparison/
www.merlintrader.com/vaxcyte-stoc...
www.merlintrader.com/vaxcyte-stoc...
Buyouts and Brazil: XP +49.9%, PCRX +44.0%, OPCH +37.2%, PTC +35.0%, PCVX +26.4%. Here's what moved this week and why.
$XP $PCRX $OPCH $PTC $PCVX #stocks #trading #stockmarket
https://confluencetradingtools.substack.com/p/what-moved-this-week-oct-5-9
Buyouts and Brazil: XP +49.9%, PCRX +44.0%, OPCH +37.2%, PTC +35.0%, PCVX +26.4%. Here's what moved this week and why.
$XP $PCRX $OPCH $PTC $PCVX #stocks #trading #stockmarket
https://confluencetradingtools.substack.com/p/what-moved-this-week-oct-5-9
On October 6, 2026, Vaxcyte entered into an underwriting agreement with Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters named therein , relating to the issuance and sale of 7,412,500 shares of Common Stock, at a price to the public of $64.00 per shar...
On October 6, 2026, Vaxcyte entered into an underwriting agreement with Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters named therein , relating to the issuance and sale of 7,412,500 shares of Common Stock, at a price to the public of $64.00 per shar...
On October 6, 2026, Vaxcyte entered into an underwriting agreement with Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters named therein , relating to the issuance and sale of 7,412,500 shares of Common Stock, at a price to the public of $64.00 per shar...
On October 6, 2026, Vaxcyte entered into an underwriting agreement with Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters named therein , relating to the issuance and sale of 7,412,500 shares of Common Stock, at a price to the public of $64.00 per shar...
Cowan Elvia (SVP, Finance & CAO) sold 19,000 shares at an average price of $86.7400 per common share. (Date: 2026-10-05)
Cowan Elvia (SVP, Finance & CAO) sold 19,000 shares at an average price of $86.7400 per common share. (Date: 2026-10-05)
Wassil Jim (EVP, Chief Scientific Ofc, COO) sold 18,000 shares at an average price of $86.7400 per common share. (Date: 2026-10-05)
Wassil Jim (EVP, Chief Scientific Ofc, COO) sold 18,000 shares at an average price of $86.7400 per common share. (Date: 2026-10-05)